KRAS and neoplasm: Importantly, murine clinical studies have shown that oncogenic signaling in Kras-driven GEMMs is crucially defined by the cooperating tumor suppressor, with loss of liver kinase B1 (Lkb1) conferring different therapeutic responses compared with loss of Trp53 (Chen et al., 2012).